{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:45:11Z","timestamp":1777355111067,"version":"3.51.4"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The risk of severe adult respiratory coronavirus-2 (SARS-CoV-2) infection and the course of the infection among individuals with common variable immunodeficiency (CVID) relative to the general population have been a matter of debate. We conducted a Danish nationwide study comparing the timing of SARS-CoV-2 vaccination, the risk of first confirmed SARS-CoV-2 infection, re-infection, and the outcome of infection among individuals with CVID relative to an age- and gender matched control group. Cox regression was used to calculate incidence rate ratios. The CVID patients received SARS-CoV-2 vaccinations earlier than those included in the population control group. Even so, the risks of both first infection and re-infection were increased among the individuals with CVID. The CVID group also had increased risk for hospital contacts due to SARS-CoV-2 infection relative to the general population. However, reassuringly, the risk of mechanical ventilation and death did not differ between the groups, but the numbers were low in both groups, making the estimates uncertain. Though this is the largest study to investigate the risk of SARS-CoV-2 infections and outcomes hereof among individuals with CVID relative to the general population, we cannot rule out minor differences in severity, which might only be detectable with an even larger sample size.<\/jats:p>","DOI":"10.3389\/fimmu.2022.994253","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T13:23:29Z","timestamp":1663939409000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: A Danish nationwide cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Terese L.","family":"Katzenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line D.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla Helberg","family":"Drabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten Schade","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Brit Eg","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"St\u00e6rkind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene Surland","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Holm","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Obel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"155478","DOI":"10.1089\/jir.2020.0210","article-title":"Role of host immune and inflammatory responses in COVID-19 cases with underlying primary immunodeficiency: A review","volume":"142","author":"Liu","year":"2021","journal-title":"J Interferon Cytokine Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.23094","article-title":"Immunodeficiency: A protective factor for COVID-19","volume":"14","author":"AlShanableh","year":"2022","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/S10875-021-01066-8","article-title":"Outcome of SARS-CoV-2 infection in 121 patients with inborn errors of immunity: A cross-sectional study","volume":"41","author":"Goudouris","year":"2021","journal-title":"J Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01077-5","article-title":"COVID-19 in the context of inborn errors of immunity: A case series of 31 patients from Mexico","volume":"41","author":"Castano-Jaramillo","year":"2021","journal-title":"J Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.614086","article-title":"Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel","volume":"11","author":"Marcus","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.15025","article-title":"Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses","volume":"77","author":"Karakoc Aydiner","year":"2022","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01065-9","article-title":"COVID-19 in patients with primary immunodeficiency","volume":"1","author":"Esenboga","year":"2021","journal-title":"J Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.12.620","article-title":"COVID-19 in patients with primary and secondary immunodeficiency: The united kingdom experience","volume":"147","author":"Shields","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00928-x\/Published","article-title":"Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency","volume":"41","author":"Delavari","year":"2021","journal-title":"J Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000786","article-title":"Mechanisms underlying host defense and disease pathology in response to severe acute respiratory syndrome (SARS)-CoV2 infection: Insights from inborn errors of immunity","volume":"21","author":"Tangye","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5802\/CRBIOL.36","article-title":"Insufficient type I IFN immunity underlieslife-threatening COVID-19 pneumonia life-threatening COVID-19 pneumonia","volume":"344","author":"Bastard","year":"2021","journal-title":"Comptes. Rendus - Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.2200413119","article-title":"The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies","volume":"119","author":"Manry","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","first-page":"77","article-title":"COVID-19 in children with inborn errors of immunity: Clinical scenarios","volume":"10","author":"Moazzen","year":"2021","journal-title":"Am J Clin Exp Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/PAI.13661","article-title":"Clinical characteristics of COVID-19 in children and young adolescents with inborn errors of immunity","volume":"33","author":"Yilmaz Topal","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: An international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/S10875-022-01264-Y","article-title":"The impact of SARS-CoV-2 infection in patients with inborn errors of immunity: The experience of the Italian primary immunodeficiencies network (IPINet)","volume":"42","author":"Giardino","year":"2022","journal-title":"J Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835770","article-title":"Risk factors for severe COVID-19 and hospital admission in patients with inborn errors of immunity - results from a multicenter nationwide study","volume":"13","author":"Milota","year":"2022","journal-title":"Article"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A possible role for b cells in COVID-19? lesson from patients with agammaglobulinemia","volume":"146","author":"Quinti","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAIP.2020.08.059","article-title":"Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma","volume":"8","author":"Jin","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2021.1957144","article-title":"Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2","volume":"53","author":"Drabe","year":"2021","journal-title":"Infect Dis (Auckl)."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAIP.2020.11.006","article-title":"COVID-19 infection in 10 common variable immunodeficiency patients in new York city","volume":"9","author":"Cohen","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.04.017","article-title":"Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity","volume":"9","author":"Milito","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B23","unstructured":"Vaccination calendar"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ajt.17142","article-title":"Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation; a Danish nationwide cohort study","author":"Overvad","year":"2022","journal-title":"J Transpl"},{"key":"B25","article-title":"The Danish civil registration system. a cohort of eight million persons","volume":"53","author":"Pedersen","year":"2006","journal-title":"Dan. Med Bull"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMED.1003874","article-title":"Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent MRNA vaccine in Denmark: A nationwide population-based cohort study","volume":"18","author":"Gram","year":"2021","journal-title":"PloS Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00575-4","article-title":"Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: A population-level observational study","volume":"397","author":"Hansen","year":"2021","journal-title":"Lancet (London England)"},{"key":"B28","unstructured":"Classifications - sundhedsdatastyrelsen"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCLINEPI.2004.03.012","article-title":"New ICD-10 version of the charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol."},{"key":"B30","unstructured":"Stata 14 | stata"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/J.EBIOM.2021.103705","article-title":"Safety and efficacy of the MRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/FMED.2020.00190\/BIBTEX","article-title":"Age-dependent risks of incidence and mortality of COVID-19 in hubei province and other parts of China","volume":"7","author":"Li","year":"2020","journal-title":"Front Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.10.2200181","article-title":"Molecular epidemiology of the SARS-CoV-2 variant omicron BA.2 Sub-lineage in Denmark, 29 November 2021 to 2 January 2022","volume":"27","author":"Fonager","year":"2022","journal-title":"Eurosurveillance"},{"key":"B34","doi-asserted-by":"publisher","first-page":"15278","DOI":"10.1038\/s41598-021-94630-6","article-title":"Comparison of COVID-19 outcomes among shielded and non-shielded populations","volume":"11","author":"Jani","year":"2021","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2115481\/SUPPL_FILE\/NEJMOA2115481_DISCLOSURES.PDF","article-title":"Duration of protection against mild and severe disease by covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/CID\/CIAC178","article-title":"Vaccine effectiveness of 3 versus 2 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) MRNA vaccines in a high-risk national population","volume":"75","author":"Butt","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B37","article-title":"Guidelines","year":"","journal-title":"Retningslinje til behandling af voksne patienter med COVID-19"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00365-6","article-title":"Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies","volume":"22","author":"Yamasoba","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac328","article-title":"Relative vaccine effectiveness of a SARS-CoV-2 MRNA vaccine booster dose against the omicron variant","author":"Butt","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02753","article-title":"Current understanding and recent developments in common variable immunodeficiency associated autoimmunity","volume":"10","author":"Gereige","year":"2019","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000789","article-title":"COVID-19 in complex common variable immunodeficiency patients affected by lung diseases","volume":"21","author":"Milito","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/SJI.12551","article-title":"Identification and characterization of a nationwide Danish adult common variable immunodeficiency cohort","volume":"85","author":"Westh","year":"2017","journal-title":"Scand J Immunol"},{"key":"B44","article-title":"[Primary antibody deficiency syndromes]","volume":"180","author":"Larsen","year":"2018","journal-title":"Ugeskr. Laeger"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.994253\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T13:23:39Z","timestamp":1663939419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.994253\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2022.994253"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.994253","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"article-number":"994253"}}